Turn Therapeutics' topical GX-03 hit EASI-50 in 93% of eczema patients at four weeks.
Bradley Burnam, Turn Therapeutics CEO
June 1, 2026 08:51 AM EDT
Turn Therapeutics' eczema drug shows rapid response in mid-stage data
Ayisha Sharma
News Reporter
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Novel Lupus Drugs Continue to Shine in Extended Early Data
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
ST-100 improves dry eye signs, symptoms in days
Radiopharmaceutical shows promise in post-Pluvicto setting
Woman 'trapped' by eczema now 'like old self again' with £12 gel
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36…
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which…
Johnson & Johnson said it discontinued a mid-stage study of its experimental drug to treat atopic dermatitis, after it…
A recently approved injectable eczema drug, Nemluvio, provides quick itch relief to patients with the maddening skin disease, a…
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according…
